Kiniksa Pharmaceuticals International share price today

Kiniksa Pharmaceuticals International, plc's share price was $96.12 at the close on 4 November 2026. It has been rising for 80 weeks. That is 57.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $38 and $96, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Kiniksa Pharmaceuticals International, plc is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 22 weeks in a row.

Over the last 8.4 years the share price moved +395% while the S&P 500 moved +182%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Kiniksa Pharmaceuticals International, plc pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Kiniksa Pharmaceuticals International is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Kiniksa Pharmaceuticals International, plc earned $25.4 M of net profit in the Jun 2026 quarter, +42.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $59.0 M. That is 10.4% of the quarter's revenue. The same quarter a year earlier earned $17.8 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

5 of the last 12 reported quarters were loss-making.

Kiniksa Pharmaceuticals International, plc reported $244 M of revenue in the Jun 2026 quarter, +55.4% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 4 years it has grown 104.8% a year on average. The last full year, FY25, came in at $678 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $841 M.

FY25 revenue was $678 M, +60.1% on the year before.

Recent pace: the last four quarters grew +59.3% on average, against 104.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +58.9%, against +57.5% a year over the last 8 quarters (stabilising).

Kiniksa Pharmaceuticals International, plc's operating margin was 11.2% in the Jun 2026 quarter, 1.7 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −406.4% and 11.4%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between −406.4% and 11.4%, and FY25's 11.4% is the highest of them.

Why the margin moved: operating margin changed −1.7 percentage points on the year while gross margin changed −0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 61% of Kiniksa Pharmaceuticals International, plc's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $138 M of operating cash against $59.0 M of profit. After $1.6 M of spending on assets, $136 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Kiniksa Pharmaceuticals International, plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.0 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $2.0 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Kiniksa Pharmaceuticals International, plc's P/E is 72.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Where the price move came from: over 3 years the price moved +81.0% a year; about −33.0% a year came from earnings growth and about +114.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Kiniksa Pharmaceuticals International, plc's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Kiniksa Pharmaceuticals International, plc earned a ROE of 10% in FY25. That is up from a low of −85% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −7,245%, a number that says nothing useful about the business.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a 8.7% net margin and 0.89× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a 8.7% net margin × 0.89× asset turnover × 1.35× leverage (assets divided by equity) ≈ 10.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

Kiniksa Pharmaceuticals International, plc has total debt of $8.9 M against shareholder equity of $654 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

9.3% of Kiniksa Pharmaceuticals International, plc's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Kiniksa Pharmaceuticals International, plc, the Z-score is 10.42. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 10.42 is well clear of the danger zone, so the balance sheet is not the risk here.

62.1 out of 100, rank 3 of 28 in Drug Manufacturers - Specialty & Generic, with 71% of the evidence available.

Kiniksa Pharmaceuticals International, plc scores 62.1 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 24.1 + 12.2 + 9 + 16.8 = 62.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Kiniksa Pharmaceuticals International ranks 3 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 62.1 out of 100.